A groundbreaking new drug injected every two months to prevent HIV is more effective than the daily pills currently used to protect again infection with the virus, researchers have announced.
In trials involving thousands of people across seven countries, long-acting injectable drug cabotegravir, developed by GlaxoSmithKline-owned ViiV Healthcare, was found to be 66% more effective than Truvada, the most commonly used daily pill, ABC News reports.
As The New York Times notes, “additional options for prevention are sorely needed”, with around 1.7 million new HIV infections recorded last year.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
But “many people are unable or unwilling to take a daily pill” to prevent infection - a strategy known as pre-exposure prophylaxis (PrEP) - “particularly in low-income countries where the coronavirus pandemic is disrupting services and access to antiretroviral drugs”, says the newspaper.
The trials of the anti-HIV jab involved “4,570 cisgender men and transgender women (people who were born male but identify as a woman) who had sex with men”, says ABC News. The participants were randomly assigned to receive Truvada, cabotegravir, placebo pills, or placebo injections.
Over the course of the three-and-a-half-year study, 39 participants who had taken Truvada became HIV positive, compared with only 13 who got cabotegravir injections, according to the HIV Prevention Trials Network, a scientific collaborative that led the research.
“This is a game changer - we can really impact HIV acquisition for people at risk,” said Dr Carlos del Rio, a professor at Emory School of Medicine in Atlanta who was involved in the study.
Harvard University researcher Dr Rochelle Walensky described the findings, presented this week at the Aids 2020 Conference, as “revolutionary”.
“It’s exciting to have another pharma company in the PrEP mix,” she added. “This will create competition and ideally drives costs down.”
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
US approves world’s first vaccine for honeybeesSpeed Read Development hailed as ‘exciting step forward’ in effort to halt decline in bee numbers
-
Now you can own your own ‘carpool karaoke’ unit
feature And other stories from the stranger side of life
-
Reader favourites
Speed Read A selection of short but sweet features from across The Week magazine
-
Home Office worker accused of spiking mistress’s drink with abortion drug
Speed Read Darren Burke had failed to convince his girlfriend to terminate pregnancy
-
In hock to Moscow: exploring Germany’s woeful energy policy
Speed Read Don’t expect Berlin to wean itself off Russian gas any time soon
-
Were Covid restrictions dropped too soon?
Speed Read ‘Living with Covid’ is already proving problematic – just look at the travel chaos this week
-
Inclusive Britain: a new strategy for tackling racism in the UK
Speed Read Government has revealed action plan setting out 74 steps that ministers will take
-
Sandy Hook families vs. Remington: a small victory over the gunmakers
Speed Read Last week the families settled a lawsuit for $73m against the manufacturer
